Ismail N, Mussa A, Al-Khreisat M, Yusoff S, Husin A, Al-Jamal H
Noncoding RNA. 2023; 9(6).
PMID: 37987364
PMC: 10660696.
DOI: 10.3390/ncrna9060068.
Lai X, Huang C, Nie X, Chen Q, Tang Y, Fu X
Front Oncol. 2021; 11:720261.
PMID: 34631548
PMC: 8493032.
DOI: 10.3389/fonc.2021.720261.
Allegra A, Ettari R, Innao V, Bitto A
Cells. 2021; 10(2).
PMID: 33672466
PMC: 7923438.
DOI: 10.3390/cells10020448.
Chen D, Yang X, Liu M, Zhang Z, Xing E
Cancer Gene Ther. 2021; 28(12):1256-1268.
PMID: 33402729
PMC: 8636266.
DOI: 10.1038/s41417-020-00291-4.
Tang H, Xu L, Cen X, Yang L, Feng J, Li G
Int J Mol Med. 2020; 45(6):1661-1672.
PMID: 32236619
PMC: 7169959.
DOI: 10.3892/ijmm.2020.4553.
Molecular Mechanisms of Bortezomib Action: Novel Evidence for the miRNA-mRNA Interaction Involvement.
Luczkowska K, Roginska D, Ulanczyk Z, Paczkowska E, Schmidt C, Machalinski B
Int J Mol Sci. 2020; 21(1).
PMID: 31948068
PMC: 6981510.
DOI: 10.3390/ijms21010350.
The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma.
Handa H, Murakami Y, Ishihara R, Kimura-Masuda K, Masuda Y
Cancers (Basel). 2019; 11(11).
PMID: 31698726
PMC: 6896016.
DOI: 10.3390/cancers11111738.
Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.
Abdi J, Rastgoo N, Chen Y, Chen G, Chang H
BMC Cancer. 2019; 19(1):975.
PMID: 31638931
PMC: 6805455.
DOI: 10.1186/s12885-019-6151-x.
Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer.
Chari N, Ivan C, Le X, Li J, Mijiti A, Patel A
J Natl Cancer Inst. 2019; 112(3):266-277.
PMID: 31124563
PMC: 7073912.
DOI: 10.1093/jnci/djz097.
Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise.
Ultimo S, Zauli G, Martelli A, Vitale M, McCubrey J, Capitani S
Oncotarget. 2018; 9(24):17238-17254.
PMID: 29682219
PMC: 5908320.
DOI: 10.18632/oncotarget.24428.
Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.
Rastgoo N, Abdi J, Hou J, Chang H
J Hematol Oncol. 2017; 10(1):121.
PMID: 28623912
PMC: 5474298.
DOI: 10.1186/s13045-017-0492-1.
Role of micro-RNAs in drug resistance of multiple myeloma.
Abdi J, Jian H, Chang H
Oncotarget. 2016; 7(37):60723-60735.
PMID: 27494872
PMC: 5312415.
DOI: 10.18632/oncotarget.11032.
Microenvironment drug resistance in multiple myeloma: emerging new players.
Di Marzo L, Desantis V, Solimando A, Ruggieri S, Annese T, Nico B
Oncotarget. 2016; 7(37):60698-60711.
PMID: 27474171
PMC: 5312413.
DOI: 10.18632/oncotarget.10849.
Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma.
Ri M
Int J Hematol. 2016; 104(3):273-80.
PMID: 27169614
DOI: 10.1007/s12185-016-2016-0.
MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
Saha M, Abdi J, Yang Y, Chang H
Oncotarget. 2016; 7(6):7149-60.
PMID: 26771839
PMC: 4872775.
DOI: 10.18632/oncotarget.6880.
Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma.
Peng J, Thakur A, Zhang S, Dong Y, Wang X, Yuan R
Tumour Biol. 2015; 36(11):8545-52.
PMID: 26032093
DOI: 10.1007/s13277-015-3600-2.
Personalization of cancer treatment using predictive simulation.
Doudican N, Kumar A, Singh N, Nair P, Lala D, Basu K
J Transl Med. 2015; 13:43.
PMID: 25638213
PMC: 4320499.
DOI: 10.1186/s12967-015-0399-y.
Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment.
Abdi J, Qiu L, Chang H
Biomark Res. 2014; 2:10.
PMID: 24910775
PMC: 4048053.
DOI: 10.1186/2050-7771-2-10.
Circulating microRNAs as biomarkers of acute stroke.
Sepramaniam S, Tan J, Tan K, DeSilva D, Tavintharan S, Woon F
Int J Mol Sci. 2014; 15(1):1418-32.
PMID: 24447930
PMC: 3907877.
DOI: 10.3390/ijms15011418.
MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.
Yan Z, Wu L, Xue K, Zhang Q, Guo Y, Romero M
Leukemia. 2013; 28(4):880-7.
PMID: 24104394
DOI: 10.1038/leu.2013.291.
